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Extrapulmonary small-cell carcinoma (EPSmCC) is a
rare disease, and involvement of the small bowel is
even more rare. Overall, EPSmCC accounts for only
0.1%–1% of all gastrointestinal tract (GIT) malignan-
cies, which mostly affect the esophagus and colon. It
is frequently metastatic at presentation, with high-grade
pathologic features and aggressive clinical behaviour.
Management strategies are varied, but chemotherapy
remains the cornerstone of treatment. Response to plati-
num-based chemotherapy is between 50% and 100%,
but relapses are almost universal, and prognosis is poor.
Here, we report the first case in the literature of a
patient with chemotherapy-related intestinal perfora-
tion from an EPSmCC of the small bowel. This patient
presented with a large abdominal mass encasing the
small bowel. The mass responded rapidly and con-
siderably to chemotherapy, but the patient’s subse-
quent course was characterized by recurring
intra-abdominal abscess formation. Current knowl-
edge of EPSmCC is reviewed, and clinical correlates
on the approach to perforation of high-grade intesti-
nal malignancies are explored.
1. INTRODUCTION
Extrapulmonary small cell carcinoma (EPSmCC) is
rare and represents a clinicopathologic entity distinct
from pulmonary small-cell carcinoma. It has been de-
scribed in all anatomic sites outside the central nerv-
ous system 1, but most commonly involves the
gastrointestinal tract (GIT), the genitourinary and re-
productive systems, the salivary glands and sinuses,
and lymph nodes 1,2. Overall, EPSmCC represents
0.1%–1% of GIT malignancies 3.
Within the GIT, most tumours occur within the large
bowel (39%), esophagus (30%), and stomach (8%);
only about 3% involve the small bowel 4. In a review
of EPSmCC of the duodenum in 2004, only 9 cases had
been reported in the literature 5.
Clinical presentation often involves weight loss and
anorexia, or site-specific symptoms such as abdomi-
nal pain, obstruction, bleeding, or mass. Staging workup
depends on the site of the primary, but often involves
computed tomography (CT) imaging of the chest, ab-
domen, and pelvis, and GIT endoscopy. Diagnosis is
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confirmed when biopsy shows small cells with scanty
cytoplasm and round nuclei combined with histologic
features typical of high-grade neuroendocrine tumours.
Staging can be defined by the tumour–node–metasta-
sis (TNM) system, but more commonly uses the Veter-
ans Administration Lung Study Group (VALSG) system
which identifies two distinct stages: limited stage (LS)
or extensive stage (ES), based on whether the disease
is confined to a locoregional anatomic location or
whether it is not.
The treatment approach has evolved from being
primarily surgical to being centered on chemotherapy,
particularly platinum-based regimens. The precise role
of surgery in LS disease is not well defined, nor have
any studies examined the role of surgery as prophy-
laxis for potential chemotherapy-induced complications
such as perforation or hemorrhage.
2. CASE PRESENTATION
A 72-year-old man presented to our hospital with a 2-
week history of lower abdominal pain, constipation,
and weight loss of 7.3 kg. One month earlier, he had
presented to another institution with a 1-month history
of fatigue and dyspnea. On that occasion, he was found
to be anemic (hemoglobin: 76 g/L), for which an en-
doscopy and colonoscopy were performed. Those tests
failed to reveal any cause for the anemia. Physical
exam demonstrated a firm, slightly tender, palpable
mass in the upper abdomen, but no hepatomegaly or
splenomegaly. There was also no jaundice or systemic
evidence of liver disease, and no palpable lymphad-
enopathy. No rales, wheezes, or areas of reduced air
entry were observed on auscultation. He had a perform-
ance status of 2.
Imaging of the abdomen by CT showed a large
heterogeneous mass appearing to arise from the small
bowel mesentery, measuring 15.7 × 26.3 × 22 cm, and
partly encasing loops of small bowel [Figure 1(A)].
No adenopathy or other significant intra-abdominal
pathology was observed. Imaging of the chest by CT
demonstrated a single 2.2 × 2.1-cm subpleural lesion
in the left lower lobe of the lung, abutting the inner
aspect of the thoracic wall, appearing to arise from the
abdomen, with no intrathoracic adenopathy. A CT-guidedOWEN and CHASEN
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biopsy of the abdominal mass demonstrated a poorly
differentiated neuroendocrine carcinoma with features
of a small-cell carcinoma a. A bone marrow biopsy
revealed no malignant cells. A bone scan and imaging
of the head by CT were negative for bone and brain
metastases respectively. A diagnosis of EPSmCC was
made, and after prompt placement of a peripherally in-
serted central catheter, treatment with etoposide (100 mg/
m2, days 1 to 3) and cisplatin (80 mg/m2, day 1) began,
with planned cycles of 21 days.
From day 1 to day 6 of chemotherapy, the patient
developed recurring fever spikes (maximum: 38.8°C),
but preliminary investigations did not reveal a source.
On day 6, he developed worsening abdominal pain,
somnolence, tachycardia, and hypotension. Peritoneal
signs were present on physical exam. Imaging of the
abdomen by CT showed small pockets of gas bubbles
at the site of the tumour, consistent with tumour necro-
sis [Figure 1(B)].
Broad-spectrum antibiotics were instituted, and
surgical consultation was requested. Surgical inter-
vention was refused because of a high perioperative
risk and impending neutropenia anticipated from the
chemotherapy.
Over the following 4 days, the patient’s clinical
picture remained tenuous. He developed acute renal
failure (creatinine rose to 188 μmol/L from a baseline
of about 110 μmol/L) and anasarca. Antibiotics were
added, ultimately including imipenem, vancomycin,
metronidazole, ciprofloxacin, and fluconazole. With
these interventions, the patient’s hemodynamics and
overall clinical picture normalized by day 10.
The patient recovered well from the foregoing
events and received his 2nd cycle of chemotherapy on
schedule. In light of the renal failure and gross edema,
to which the cisplatin may have contributed because
of its nephrotoxicity and the large fluid volumes given
with the drug, cisplatin was replaced with carboplatin
(area under the curve: 6). Antibiotics were discontin-
ued, adequate diuresis was achieved, and the patient
was discharged home on day 8 of cycle 2.
The patient returned to clinic on day 16 of cycle 2
with complaints of fatigue and dyspnea. He received 2
units of packed red blood cells because of a hemoglobin
level of 85 g/L, and repeat CT imaging of the abdomen
was requested to evaluate tumour response. On the
patient’s return to the clinic 1 week later (day 22), his
symptoms had not improved. Fever and worsening ab-
dominal pain were now present. The abdominal CT
demonstrated a large 25 × 16-cm cystic abdominal mass
with air–fluid levels at the site of the previous tumour
[Figure 1(C)], and leucocytosis was found (17.8 × 109).
The patient was sent for urgent CT-guided abdominal
drainage, which removed more than 4 L purulent ma-
terial, and intravenous antibiotics were administered.
Symptoms improved immediately with drainage. The
abdominal exudate grew Klebsiella, Bacteroides, En-
terococcus, and Staphylococcus aureus.
After 24 hours of observation in the emergency
room, the patient was discharged home with a pre-
scription for 2 weeks of oral antibiotics consisting of
ciprofloxacin, metronidazole, and amoxicillin with
clavulanic acid. The drain was removed after 8 days.
Imaging by CT on the day before drain removal showed
complete resolution of the abscess and significant re-
duction in tumour size (Figure 1(D)].
The patient’s 3rd cycle of chemotherapy occurred
on schedule and without incident, and at the time of
writing, he was beginning a 4th cycle.
3. DISCUSSION
Like its counterpart in the lung, EPSmCC has an aggres-
sive clinical presentation and high-grade pathologic fea-
tures. It is frequently metastatic at presentation, and
prognosis for these tumours is poor, particularly for
EPSmCC of the GIT. In this location, the tumour tends to
demonstrate ES disease and high-grade histology on
presentation more frequently than EPSmCC of other sites
does 1,3. For GIT EPSmCC, survival for untreated pa-
tients is only several weeks; it is 6–12 months for patients
a Stain results: periodic acid Schiff (PAS) and PAS after diastase,
negative; cytokeratin AE1/3 and CK8/18, positive; cytokeratin
CK7, negative; cytokeratin CK20, negative; prostate-specific
antigen, negative; thyroid transcription factor 1, negative;
synaptophysin and neuron-specific enolase, positive; CD10 and
Bcl16, negative; desmin, negative; CD45 and CD20, negative;
Bcl2, positive; Ki67, 70%–80%; Fli1, negative; CD99, positive;
Wilms tumour 1, negative.
FIGURE 1   Extrapulmonary small-cell carcinoma involving the small
bowel. (A) Large anterior abdominal tumour seen at initial
presentation. (B) After initiation of chemotherapy, gas bubbles
(arrows) indicate sites of tumour necrosis. (C) A large abscess
develops from perforation of the small bowel. (D) Reduction of tumour
size after 2 cycles of chemotherapy and drainage of the abscess.CHEMOTHERAPY-INDUCED SMALL BOWEL PERFORATION
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receiving treatment 3. Identified prognostic factors in-
clude stage of the disease (by either the VALSG or the
TNM staging system), receipt of systemic treatment, and
for esophageal EPSmCC, age and tumour size 6.
Treatment strategies are varied and include surgi-
cal, pharmacologic, radiotherapeutic, and combined
approaches. However, chemotherapy, either alone or
as part of a combined approach, has emerged as the
cornerstone of treatment 1–4,6,7. Various drug combi-
nations have been tried, mostly including cisplatin,
etoposide, cyclophosphamide, or doxorubicin as the
main agents. Response rates of 50%–100% have been
reported, with the best responses seen with platinum-
based regimens 3. These response rates are high, but
they are generally less than the rates seen with pulmo-
nary small-cell carcinoma, perhaps reflecting the preva-
lence of mixed histology in 30%–40% of specimens 4,6.
Unfortunately, despite the high tumour response, almost
all patients relapse and succumb; however, reports of
long-term survivors have been published 8–10.
In the present case, rapid response of a large, in-
testinal-associated EPSmCC to platinum-based chemo-
therapy was complicated by intestinal perforation.
Perforation is evidenced by the temporal correlation
between chemotherapy administration, radiologic evi-
dence of tumour necrosis, clinical manifestations of
sepsis and acute abdomen, and subsequent polymicro-
bial intra-abdominal cultures that grew mostly enteric
organisms. This sequence supports a pathophysiologic
mechanism in which wall integrity of the small bowel
is lost as the tumour rapidly necroses in response to
chemotherapy. It is also possible, however, that the
result could be related to an agent-specific risk, as is
seen with bevacizumab 11. Recurrence of the abscess
during the 2nd cycle of chemotherapy suggests the need
for a more definitive treatment strategy.
Bowel perforation has been extensively described
in metastatic lung cancer 11–13, but the present report
is the first of such a case for primary small-cell carci-
noma of the small bowel. Thus, no current studies are
available to guide clinical management. It may there-
fore be useful to examine the literature of other highly
chemo-responsive tumours of the GIT—namely, lym-
phomas. Perforation is a common complication in this
group of diseases, frequently seen at disease presenta-
tion and portending a poor prognosis 14,15. No surgical
benefit is observed for gastric lymphomas, but failure-
free survival is significantly correlated with resection
of intestinal lymphomas 16. However, the benefit in fail-
ure-free survival in the aforementioned study did not
result from prevention of perforation, because only 1
case of bowel perforation occurred. Nevertheless, sur-
gical resection of intestinal lymphomas before chemo-
therapy is currently recommended in most cases 17.
4. CONCLUSIONS
Extrapleural small-cell carcinoma of the GIT is rare and
portends a poor prognosis. Response to chemotherapy
is strong and often rapid, but relapses are almost uni-
versal, with few survivors beyond 2 years. In the case
reported here, high chemosensitivity resulted in treat-
ment-related perforation of the small bowel, sepsis,
and abscess recurrence during a subsequent cycle of
chemotherapy. Based on the literature of GIT lympho-
mas, we suggest that surgery be considered part of the
management approach in some patients with EPSmCC
of the small bowel. As a theoretical framework, sur-
gery should be advised if the risk of fatal complica-
tions such as perforation or hemorrhage outweigh the
surgical mortality and morbidity. Given the lack of fea-
sibility of prospective trials for this rare entity, large
retrospective analyses are needed to better character-
ize the risk factors for perforation among patients with
EPSmCC of the GIT and to help guide future clinical
management.
5. ACKNOWLEDGMENT
Written consent for publication was obtained from the
patient.
6. REFERENCES
1. Lee SS, Lee JL, Ryu MH, et al. Extrapulmonary small cell
carcinoma: single center experience with 61 patients. Acta Oncol
2007;46:846–51.
2. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell car-
cinoma. Cancer 1997;79:1729–36.
3. Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carci-
nomas of the gastrointestinal tract: a review. J Clin Oncol
2004;22:2730–9.
4. Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen
DP. Small-cell carcinoma of the gastrointestinal tract: a retro-
spective study of 64 cases. Br J Cancer 2004;90:1720–6.
5. Sata N, Tsukahara M, Koizumi M, et al. Primary small-cell
neuroendocrine carcinoma of the duodenum—a case report and
review of literature. World J Surg Oncol 2004;2:28.
6. Casas F, Ferrer F, Farrús B, Casals J, Biete A. Primary small
cell carcinoma of the esophagus: a review of the literature with
emphasis on therapy and prognosis. Cancer 1997;80:1366–
72.
7. Van Der Gaast A, Verwey J, Prins E, Splinter TA. Chemo-
therapy as treatment of choice in extrapulmonary undifferenti-
ated small cell carcinomas. Cancer 1990;65:422–4.
8. Arai K, Matsuda M. Gastric small-cell carcinoma in Japan: a
case report and review of the literature. Am J Clin Oncol
1998;21:458–61.
9. Nishimaki T, Suzuki T, Nakagawa S, Watanabe K, Aizawa K,
Hatakeyama K. Tumor spread and outcome of treatment in
primary esophageal small cell carcinoma. J Surg Oncol
1997;64:130–4.
10. Yachida S, Matsushita K, Usuki H, Wanibuchi H, Maeba T,
Maeta H. Long-term survival after resection for small cell car-
cinoma of the esophagus. Ann Thorac Surg 2001;72:596–7.
11. Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G.
Perforated viscus in a patient with non-small cell lung cancer
receiving bevacizumab. J Thorac Oncol 2007;2:571–3.OWEN and CHASEN
301 301 301 301 301
CURRENT ONCOLOGY—VOLUME 15, NUMBER 6
12. Garwood RA, Sawyer MD, Ledesma EJ, Foley E, Claridge JA.
A case and review of bowel perforation secondary to meta-
static lung cancer. Am Surg 2005;71:110–16.
13. Sakorafas GH, Pavlakis G, Grigoriadis KD. Small bowel perfo-
ration secondary to metastatic lung cancer: a case report and
review of the literature. Mt Sinai J Med 2003;2:130–2.
14. Bairey O, Ruchlemer R, Shpilberg O. Non-Hodgkin’s lympho-
mas of the colon. Isr Med Assoc J 2006;8:832–5.
15. Waisberg J, Bromberg SH, Franco MI, et al. Primary non-
Hodgkin lymphoma of the right colon: a retrospective clinical-
pathological study. Int Surg 2001;86:20–5.
16. Gobbi PG, Ghirardelli ML, Cavalli C, et al. The role of surgery
in the treatment of gastrointestinal lymphomas other than low-
grade MALT lymphomas. Haematologica 2000;85:372–80.
17. Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin’s
lymphoma: a multicenter prospective clinical study from the
German Study Group on Intestinal non-Hodgkin’s Lymphoma.
J Clin Oncol 2003;21:2740–6.
Correspondence to: Martin Chasen, Cancer Nutrition–
Rehabilitation Programme, Gerald Bronfman Centre
for Clinical Research in Oncology, 546 Pine Avenue
West, Montreal, Quebec  H2W 1S6.
E-mail: martin.chasen@muhc.mcgill.ca
* Department of Medical Oncology, McGill Univer-
sity Health Centre, McGill University, Montreal, QC.